Tanshinone II A inhibits tat-induced HIV-1 transactivation through redox-regulated AMPK/Nampt pathway

Journal of Cellular Physiology

Volumn 229, Issue 9, 2014, Pages 1193-1201

  Zhang, Hong Sheng ^a   Chen, Xin Yu ^a   Wu, Tong Chao ^a   Zhang, Feng Juan ^a  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; SMALL INTERFERING RNA; TANSHINONE IIA; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR NRF2;

ARTICLE; CELL LEVEL; CONTROLLED STUDY; DEPLETION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSACTIVATION; UPREGULATION;

AMP-ACTIVATED PROTEIN KINASES; ANTI-HIV AGENTS; CYTOKINES; DITERPENES, ABIETANE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, VIRAL; GLUTATHIONE; HELA CELLS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; NF-E2-RELATED FACTOR 2; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIRTUIN 1; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; VIRUS ACTIVATION;

EID: 84901242613     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24552     Document Type: Article

References (46)

1. Abd-Elazem IS, Chen HS, Bates RB, Huang RC. 2012. Isolation of two highly potent and non-toxic inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase from Salvia miltiorrhiza. Antiviral Res 55:91-106.
2. Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A, Garuti A, D'Urso A, Selmo M, Benvenuto F, Cea M, Zoppoli G, Moran E, Soncini D, Ballestrero A, Sordat B, Patrone F, Mostoslavsky R, Uccelli A, Nencioni A. 2009. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One 4:e7897.
3. Burgos ES. 2011. NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism. Curr Med Chem 18:1947-1961.
4. Chen XY, Zhang HS, Wu TC, Sang WW, Ruan Z. 2013. Down-regulation of NAMPT expression by miR-182 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation. Int J Biochem Cell Biol 45:292-298.
5. Dahl TB, Holm S, Aukrust P, Halvorsen B. 2012. Visfatin/NAMPT: A multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr 32:229-243.
6. Demonté D, Quivy V, Colette Y, Van Lint C. 2004. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol 68:1231-1238.
7. Gallí M, Van Gool F, Rongvaux A, Andris F, Leo O. 2010. The nicotinamide phosphoribosyltransferase: A molecular link between metabolism, inflammation, and cancer. Cancer Res 70:8-11.
8. Gatignol A. 2007. Transcription of HIV: Tat and cellular chromatin. Adv Pharmacol 55:137-159.
9. Grahnert A, Grahnert A, Klein C, Schilling E, Wehrhahn J, Hauschildt S. 2011. Review: NAD+: A modulator of immune functions. Innate Immun 17:212-233.
10. Harrich D, McMillan N, Munoz L, Apolloni A, Meredith L. 2006. Will diverse Tat interactions lead to novel antiretroviral drug targets?. Curr Drug Targets 7:1595-1606.
11. Harrich D, Ulich C, Garcia-Martine L, Gaynor RB. 1997. Tat is required for efficient HIV-1 reverse transcription. EMBO J 16:1224-1235.
12. Hejnar J, Hirsch I. 2010. New inhibitors of HDAC to purge latent HIV-1 reservoir. Epigenomics 2:505-506.
13. Hwang JW, Yao H, Caito S, Sundar IK, Rahman I. 2013a. Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic Biol Med 61C:95-110.
14. Hwang SL, Yang JH, Jeong YT, Kim YD, Li X, Lu Y, Chang YC, Son KH, Chang HW. 2013b. Tanshinone II A improves endoplasmic reticulum stress-induced insulin resistance through AMP-activated protein kinase. Biochem Biophys Res Commun 430:1246-1252.
15. Imai S. 2011. Dissecting systemic control of metabolism and aging in the NAD World: The importance of SIRT1 and NAMPT-mediated NAD biosynthesis. FEBS Lett 585:1657-1662.
16. Inoki K, Kim J, Guan KL. 2012. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 52:381-400.
17. Kauppinen TM, Gan L, Swanson RA. 2013. Poly(ADP-ribose) polymerase-1-induced NAD+ depletion promotes nuclear factor-κB transcriptional activity by preventing p65 de-acetylation. Biochim Biophys Acta 1833:1985-1991.
18. Kwon HS, Brent MM, Getachew R, Jayakumar P, Chen LF, Schnolzer M, McBurney MW, Marmorstein R, Greene WC, Ott M. 2008. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 3:158-167.
19. Liu TF, Yoza BK, El Gazzar M, Vachharajani VT, McCall CE. 2011. NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance. J Biol Chem 286:9856-9864.
20. Ma Q. 2013. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53:401-426.
21. Massari S, Sabatini S, Tabarrini O. 2013. Blocking HIV-1 replication by targeting the Tat-hijacked transcriptional machinery. Curr Pharm Des 19:1860-1879.
22. Matalon S, Rasmussen TA, Dinarello CA. 2011. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 17:466-472.
23. Mbonye U, Karn J. 2011. Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res 9:554-567.
24. Morris BJ. 2013. Seven sirtuins for seven deadly diseases of aging. Free Radic Biol Med 56:133-171.
25. Nekhai S, Jeang KT. 2006. Transcriptional and posttranscriptional regulation of HIV-1 gene expression: role of cellular factor. Future Microbiol 4:417-426.
26. Ott M, Geyer M, Zhou Q. 2011. The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe 10:426-435.
27. Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, Dorr A, Hetzer-Egger C, Henklein P, Frye R, McBurney MW, Hruby H, Jung M, Verdin E, Ott M. 2005. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 3:e41.
28. Pan C, Lou L, Huo Y, Singh G, Chen M, Zhang D, Wu A, Zhao M, Wang S, Li J. 2011. Salvianolic acid B and tanshinone II A attenuate myocardial ischemia injury in mice by NO production through multiple pathways. Ther Adv Cardiovasc Dis 5:99-111.
29. Park JY, Kim JH, Kim YM, Jeong HJ, Kim DW, Park KH, Kwon HJ, Park SJ, Lee WS, Ryu YB. 2012. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases. Bioorg Med Chem 20:5928-5935.
30. Razooky BS, Weinberger LS. 2011. Mapping the architecture of the HIV-1 Tat circuit: A decision-making circuit that lacks bistability and exploits stochastic noise. Methods 53:68-77.
31. Stevens M, De Clercq E, Balzarini J. 2006. The regulation of HIV-1 transcription: Molecular targets for chemotherapeutic intervention. Med Res Rev 26:595-625.
32. Tian XH, Wu JH. 2013. Tanshinone derivatives: A patent review (January 2006-September 2012). Expert Opin Ther Pat 23:19-29.
33. Tripathy MK, Abbas W, Herbein G. 2011. Epigenetic regulation of HIV-1 transcription. Epigenomics 3:487-502.
34. Van den Bergh R, Florence E, Vlieghe E, Boonefaes T, Grooten J, Houthuys E, Tran HT, Gali Y, De Baetselier P, Vanham G, Raes G. 2010. Transcriptome analysis of monocyte-HIV interactions. Retrovirology 7:53.
35. Van Gool F, Gallí M, Gueydan C, Kruys V, Prevot PP, Bedalov A, Mostoslavsky R, Alt FW, De Smedt T, Leo O. 2009. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med 15:206-210.
36. Victoriano AF, Okamoto T. 2012. Transcriptional control of HIV replication by multiple modulators and their implication for a novel antiviral therapy. AIDS Res Hum Retroviruses 228:125-138.
37. Wang P, Zhou S, Xu L, Lu Y, Yuan X, Zhang H, Li R, Fang J, Liu P. 2013. Hydrogen peroxide-mediated oxidative stress and collagen synthesis in cardiac fibroblasts: Blockade by tanshinone II A. J Ethnopharmacol 145:152-161.
38. Wightman F, Ellenberg P, Churchill M, Lewin SR. 2012. HDAC inhibitors in HIV. Immunol Cell Biol 90:47-54.
39. Xu S, Liu P. 2013. Tanshinone II-A: New perspectives for old remedies. Expert Opin Ther Pat 23:149-153.
40. Yeung F, Hoberg JE, Ramsey CS. 2004. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369-2380.
41. Zhang HS, Li HY, Zhou Y, Wu MR, Zhou HS. 2009a. Nrf2 is involved in inhibiting Tat-induced HIV-1 long terminal repeat transactivation. Free Radic Biol Med 47:261-268.
42. Zhang HS, Sang WW, Ran Z, Wang YO. 2011. Akt/Nox2/NF-κB signaling pathway is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation. Arch Biochem Biophys 505:266-272.
43. Zhang HS, Sang WW, Wang YO, Liu W. 2010. Nicotinamide phosphoribosyltransferase/sirtuin 1 pathway is involved in human immunodeficiency virus type 1 Tat-mediated long terminal repeat transactivation. J Cell Biochem 110:1464-1470.
44. Zhang HS, Wang SQ. 2007. Nrf2 is involved in the effect of tanshinone II A on intracellular redox status in human aortic smooth muscle cells. Biochem Pharmacol 73:1358-1366.
45. Zhang HS, Wu MR. 2009. SIRT1 regulates Tat-induced HIV-1 transactivation through activating AMP-activated protein kinase. Virus Res 146:51-57.
46. Zhang HS, Zhou Y, Wu MR, Zhou HS, Xu F. 2009b. Resveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD(+)-dependent SIRT1 activity. Life Sci 85:484-489.